DGAP-News

American Journal of Surgery Publishes Analysis Corroborating Successful Outcomes for novoGI Compression Anastomosis

novoGI Inc.

10.01.2013 21:11

---

Low Leak Rates of 3.2% Reported in 1180 Patients

ATLANTA, 2013-01-10 21:11 CET (GLOBE NEWSWIRE) --
novoGI Inc. today announced that the American Journal of Surgery published the
results of a major 1180-patient multinational, multicenter analysis of the
company´s compression anastomosis technology. Significant findings reported in
´Compression Anastomosis Ring Device in Colorectal Anastomosis: A Review of
1,180 Patients´ include low leak rates of 3.2% overall for end-to-end
anastomosis and only 1.9% for low anterior resection (LAR) procedures with the
company´s novoGI(tm) ColonRing device.1

In addition to the low leak rates reported, median length of hospital stay was
6 days and median time for natural excretion of the ColonRing was 8 days.
Summarizing the results, the authors stated, ´Our study involved the largest
number of end-to-end colorectal anastomoses using the ColonRing device to date.
The rate of anastomotic leak is relatively low with the use of the ColonRing
for both open and laparoscopic colorectal anastomoses. The device failure rate
is very low, and problems with ring expulsion are not significant. End-to-end
colorectal anastomosis with the ColonRing is feasible and safe and may lead to
decreased anastomotic complications in low anastomoses resulting in lower
morbidity and lower mortality.´

´The important results reported in this latest publication of the American
Journal of Surgery are consistent with peer-review clinical evidence
demonstrating better outcomes for anastomosis with the novoGI(tm) ColonRing, ´
commented novoGI President and Chief Executive Officer, Gavriel D. Meron.
´These results support the goal of displacing the use of staples in colorectal
anastomoses and creating a new standard of care.´

1.  Masoomi H, Luo R, Mills S, Carmichael JC, Senagore AJ, Stamos MJ.
Compression anastomosis ring device in colorectal anastomosis: a review of
1,180 patients. Am J Surg. 2013. [Published online ahead of print]
doi:10.1016/j.amjsurg.2012.03.013. Available at:
http://www.americanjournalofsurgery.com/article/S0002-9610(12)00580-6/abstract

About novoGI

novoGI is focused on providing an expanding range of solutions for GI disease
management through a globally branded, high quality, market driven company. The
U.S. headquarters are in Atlanta, Georgia; research, development and
manufacturing facilities in Netanya, Israel; and its European headquarters are
near Paris, France. The company´s website is www.novoGI.com.

NOVOGI, the NOVOGI logo, the GI logo, and DEFINING THE FUTURE are trademarks
and/or registered trademarks of novoGI Inc.

For further information contact: [e-mail]
News Source: NASDAQ OMX

10.01.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:     English
Company:      novoGI Inc.
              
               
              Israel
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9902064198
WKN:          

End of Announcement                             DGAP News-Service

---